Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study.

Chang-Min LeeMoon-Won YooYoung-Gil SonSung Jin OhJong-Han KimHyoung-Il KimJoong-Min ParkHoon HurYe Seob JeeSun-Hwi HwangSung-Ho JinSang Eok LeeJi-Ho ParkKyung Won SeoSungsoo ParkChang Hyun KimIn Ho JeongHan Hong LeeSung Il ChoiSang-Il LeeChan Young KimIn-Hwan KimMyoung-Won SonKyung Ho PakSungsoo KimMoon-Soo LeeJae-Seok Min

Published in: Journal of gastric cancer (2020)

S-1 and CAPOX AC regimens did not show significant difference in over-5yr DFS after curative gastrectomy in patients with stage II or III GC. The pT, pN stage, and completion of planned chemotherapy were prognostic factors for GC recurrence.

Keyphrases

prognostic factors
locally advanced
rectal cancer
randomized controlled trial
open label
gas chromatography
clinical trial
phase ii study
cross sectional
mass spectrometry
metastatic breast cancer
study protocol